Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

890810C

Avanti

18:0 DDAB

Avanti Polar Lipids 890810C

Synonym(s):

Dimethyldioctadecylammonium (Bromide Salt)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C38H80NBr
CAS Number:
3700-67-2
Molecular Weight:
630.95
UNSPSC Code:
12352211
NACRES:
NA.25

form

liquid

packaging

pkg of 1 × 2.5 mL (890810C-25mg)
pkg of 2 × 4 mL (890810C-200mg)

manufacturer/tradename

Avanti Polar Lipids 890810C

concentration

10 mg/mL (890810C-25mg)
25 mg/mL (890810C-200mg)

lipid type

cationic lipids
transfection

shipped in

dry ice

storage temp.

−20°C

SMILES string

CCCCCCCCCCCCCCCCCC[N+](CCCCCCCCCCCCCCCCCC)(C)C.[Br-]

InChI

1S/C38H80N.BrH/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-37-39(3,4)38-36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2;/h5-38H2,1-4H3;1H/q+1;/p-1

InChI key

PSLWZOIUBRXAQW-UHFFFAOYSA-M

General description

18:0 DDAB is a cationic lipid and a quaternary ammonium salt. The hydrocarbon tails are saturated, unlike the ionizable lipids. 18:0 DDAB acts as an active nasal adjuvant.

Application

18:0 DDAB or Dimethyldioctadecylammonium (Bromide Salt) has been used to perform transfection of S2 cells.

Biochem/physiol Actions

18:0 DDAB is a surface-active molecule, used as an adjuvant to induce a systemic immune response. It is non-toxic.

Packaging

5 mL Clear Glass Sealed Ampule (890810C-200mg)
5 mL Clear Glass Sealed Ampule (890810C-25mg)

Other Notes

For R&D use only. Not for drug, household, or other uses.

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

also commonly purchased with this product

Product No.
Description
Pricing

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

Target Organs

Central nervous system

Storage Class Code

6.1D - Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

WGK

WGK 3

Flash Point(F)

does not flash

Flash Point(C)

does not flash

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sarah E McNeil et al.
Journal of pharmaceutical sciences, 100(5), 1856-1865 (2011-03-05)
The adjuvanticity of liposomes can be directed through formulation to develop a safe yet potent vaccine candidate. With the addition of the cationic lipid dimethyldioctadecylammonium bromide (DDA) to stable neutral distearoylphosphatidylcholine (DSPC):cholesterol (Chol) liposomes, vesicle size reduces while protein entrapment
Hong Yu et al.
Infection and immunity, 78(5), 2272-2282 (2010-03-17)
Major impediments to developing a Chlamydia vaccine lie in identifying immunologically relevant T-cell antigens and delivery in a manner to stimulate protective immunity. Using an immunoproteomic approach, we previously identified three immunodominant Chlamydia T-cell antigens (PmpG-1, PmpE/F-2, and RplF). Because
Ana Cristina Norberto Oliveira et al.
ACS applied materials & interfaces, 6(9), 6977-6989 (2014-04-10)
This study describes a novel liposomal formulation for siRNA delivery, based on the mixture of the neutral lipid monoolein (MO) and cationic lipids of the dioctadecyldimethylammonium (DODA) family. The cationic lipids dioctadecyldimethylammonium bromide (DODAB) and chloride (DODAC) were compared in
Anne Gallez et al.
International journal of pharmaceutics, 573, 118861-118861 (2019-11-26)
The encapsulation into liposomes of several types of molecules presents the advantages to protect the activity of these molecules and to target specific tissues. Nevertheless, a major obstacle remains the incomplete understanding of nano-bio interactions. Specifically, the impact that inclusion
Hong Yu et al.
Infection and immunity, 80(4), 1510-1518 (2012-02-01)
Major impediments to a Chlamydia vaccine lie in discovering T cell antigens and polarizing adjuvants that stimulate protective immunity. We previously reported the discovery of three T cell antigens (PmpG, PmpF, and RplF) via immunoproteomics that elicited protective immunity in
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service